Jianjun Chen

6.3k total citations · 2 hit papers
130 papers, 4.7k citations indexed

About

Jianjun Chen is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Jianjun Chen has authored 130 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 44 papers in Oncology and 42 papers in Organic Chemistry. Recurrent topics in Jianjun Chen's work include Synthesis and biological activity (27 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Jianjun Chen is often cited by papers focused on Synthesis and biological activity (27 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Jianjun Chen collaborates with scholars based in China, United States and Australia. Jianjun Chen's co-authors include Wěi Li, Duane D. Miller, Yan Lü, Min Xiao, Binbin Cheng, James T. Dalton, Yichang Ren, Jin Wang, Xiaopeng Peng and Weien Yuan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Advanced Functional Materials.

In The Last Decade

Jianjun Chen

125 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

2012 626 citations Jianjun Chen, Wěi Li et al. profile →
HDAC-targeting epigenetic modulators for cancer immunotherapy

2024 58 citations Binbin Cheng, Yao Xiao et al. European Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jianjun Chen China	38	2.0k	1.9k	1.1k	530	379	130	4.7k
Chanakya Nath Kundu India	38	2.1k 1.0×	767 0.4×	990 0.9×	385 0.7×	363 1.0×	124	4.1k
Sushil K. Kashaw India	29	1.6k 0.8×	1.6k 0.8×	1.2k 1.1×	463 0.9×	676 1.8×	131	4.7k
Bin Yu China	46	3.7k 1.8×	2.8k 1.5×	999 0.9×	258 0.5×	443 1.2×	220	7.2k
Pranav Gupta United States	29	1.8k 0.9×	702 0.4×	2.1k 2.0×	413 0.8×	253 0.7×	77	3.9k
Roger M. Phillips United Kingdom	38	2.1k 1.0×	1.7k 0.9×	1.4k 1.4×	454 0.9×	189 0.5×	162	4.9k
Wenfang Xu China	37	3.0k 1.5×	1.7k 0.9×	1.6k 1.5×	185 0.3×	266 0.7×	266	5.2k
Paul M. Loadman United Kingdom	37	2.1k 1.0×	585 0.3×	1.1k 1.0×	410 0.8×	234 0.6×	152	4.0k
Vladimı́r Kryštof Czechia	35	1.7k 0.8×	1.4k 0.7×	1.1k 1.0×	335 0.6×	117 0.3×	160	4.2k
Shaloam Dasari United States	8	2.0k 1.0×	798 0.4×	1.7k 1.6×	388 0.7×	184 0.5×	12	4.8k
Patric J. Jansson Australia	42	2.6k 1.3×	981 0.5×	2.4k 2.2×	192 0.4×	183 0.5×	85	5.5k

Countries citing papers authored by Jianjun Chen

Since Specialization

Citations

This map shows the geographic impact of Jianjun Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianjun Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianjun Chen more than expected).

Fields of papers citing papers by Jianjun Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianjun Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianjun Chen. The network helps show where Jianjun Chen may publish in the future.

Co-authorship network of co-authors of Jianjun Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Jianjun Chen. A scholar is included among the top collaborators of Jianjun Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianjun Chen. Jianjun Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Binbin, et al.. (2025). Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates. European Journal of Medicinal Chemistry. 287. 117347–117347. 1 indexed citations

Wu, Chengyong, Ling Li, Jin Liu, et al.. (2024). Discovery of novel thiophene[3,2-d]pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma. European Journal of Medicinal Chemistry. 277. 116791–116791. 6 indexed citations

Zhao, Zean, Xinhua Chen, Jiajun Luo, et al.. (2024). Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents. European Journal of Medicinal Chemistry. 277. 116753–116753. 3 indexed citations

Cheng, Jinmei, Zichao Yang, Ting Liu, et al.. (2024). Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects. Journal of Medicinal Chemistry. 67(15). 13067–13088. 9 indexed citations

Cheng, Binbin, et al.. (2024). HDAC-targeting epigenetic modulators for cancer immunotherapy. European Journal of Medicinal Chemistry. 265. 116129–116129. 58 indexed citations breakdown →

Cheng, Binbin, et al.. (2024). Recent advances in developing targeted protein degraders. European Journal of Medicinal Chemistry. 284. 117212–117212. 8 indexed citations

Cheng, Binbin, et al.. (2024). Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020–2024). European Journal of Medicinal Chemistry. 283. 117141–117141. 11 indexed citations

Xu, Chenglong, et al.. (2023). Rhizoaspergillin A and Rhizoaspergillinol A, including a Unique Orsellinic Acid–Ribose–Pyridazinone-N-Oxide Hybrid, from the Mangrove Endophytic Fungus Aspergillus sp. A1E3. Marine Drugs. 21(11). 598–598. 3 indexed citations

Cheng, Binbin, et al.. (2022). Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. European Journal of Medicinal Chemistry. 230. 114109–114109. 78 indexed citations

10.

Li, Ling, Sijie Yuan, Lin Lin, et al.. (2022). Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD). Bioorganic Chemistry. 120. 105619–105619. 9 indexed citations

11.

Zhang, Hong‐Yu, Jianjun Chen, Congcong Lu, et al.. (2021). Visible-Light-Induced C(sp²)–C(sp³) Cross-Dehydrogenative-Coupling Reaction of N-Heterocycles with N-Alkyl-N-methylanilines under Mild Conditions. The Journal of Organic Chemistry. 86(17). 11723–11735. 29 indexed citations

12.

Chen, Jianjun, Xiaojia Wu, Lü Chen, et al.. (2020). Analysing the Clinical Features of Pneumomediastinum Associated with Diabetic Ketoacidosis in 79 Cases. SHILAP Revista de lepidopterología. 1 indexed citations

13.

Chen, Jianjun, et al.. (2020). Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. SHILAP Revista de lepidopterología. 3 indexed citations

14.

Chen, Jianjun, Bo Sun, Jian Wu, & Du Cheng. (2020). ONECUT2 Accelerates Tumor Proliferation Through Activating ROCK1 Expression in Gastric Cancer. SHILAP Revista de lepidopterología. 1 indexed citations

15.

Cheng, Binbin, Yichang Ren, Xiaoge Niu, et al.. (2020). Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents. Journal of Medicinal Chemistry. 63(15). 8338–8358. 66 indexed citations

16.

Li, Gang, et al.. (2020). Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors. Current Medicinal Chemistry. 28(3). 607–627. 32 indexed citations

17.

Cheng, Binbin, et al.. (2020). Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. European Journal of Medicinal Chemistry. 213. 113058–113058. 28 indexed citations

18.

Chen, Jingxuan, Sibo Jiang, Jin Wang, et al.. (2019). A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism. Drug Metabolism Reviews. 51(2). 178–195. 63 indexed citations

19.

Zhang, Qi, et al.. (2017). A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST‐segment elevation myocardial infarction. Journal of Interventional Cardiology. 31(2). 136–143. 25 indexed citations

20.

Wang, Jin, Jianjun Chen, Duane D. Miller, & Wěi Li. (2013). Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma. Molecular Cancer Therapeutics. 13(1). 16–26. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact